J&J draws FDA rebuke for misstating Inlexzo’s bladder-sparing benefits

JNJ
The notice is the second untitled letter that the FDA has sent to J&J this year. (Jeff Schear/Getty Images)

The FDA has slammed Johnson & Johnson over misleading claims about its bladder cancer drug Inlexzo, accusing the pharma company of basing statements on uninterpretable data.

In an untitled letter posted this week, the FDA laid out (PDF) concerns with the efficacy section of the Inlexzo healthcare provider website. The webpage stated that Inlexzo is designed for patients seeking bladder preservation, and that 84% of patients who had a complete response to the drug did not undergo radical cystectomy. Physicians remove the bladder in radical cystectomy procedures. 

The statements “misleadingly suggest that the SunRISe-1 study provided interpretable results” regarding Inlexzo’s effect on the need for radical cystectomy, the FDA said. Noting the trial’s single-arm design, the FDA argued that SunRISe-1 was incapable of establishing improvement on the time-to-event endpoint. The agency wants to see an appropriate comparator to show Inlexzo is driving the observed effect. 

The FDA raised public health concerns about making misleading representations of Inlexzo’s benefits in the patient population. Radical cystectomy is the preferred treatment in the population. Patients may seek alternatives because the procedure carries a high risk of complications, but delaying or avoiding surgery may increase the risk of disease progression, the FDA said. 

J&J’s webpage noted the potentially lethal consequences of delaying radical cystectomy and included a disclaimer that the analysis was exploratory. However, the statements failed to address the FDA’s concerns with the efficacy claims. 

The FDA flagged other issues with J&J’s claims about the effects of Inlexzo on muscle-invasive bladder cancer (MIBC). J&J stated that 92% of evaluable patients receiving Inlexzo didn’t progress to MIBC. The FDA views the statement as misleading.

“By presenting this information on the ‘Efficacy’ webpage and omitting material information to explain that the data are merely supportive of a known warning, the webpage misleadingly suggests that the results described above represent a demonstrated efficacy outcome of Inlexzo when this has, in fact, not been demonstrated,” the agency said.

The notice is the second untitled letter that the FDA has sent to J&J’s Janssen Biotech unit this year. The agency, which stepped up its enforcement of marketing rules last year, contacted J&J in February about a TV ad for Tremfya. J&J addressed (PDF) the violations. The FDA gave J&J 15 working days to respond to its concerns about the Inlexzo website.